Completed PHASE3 INTERVENTIONAL 2-arm NCT01099436

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients (NEO-ZOTAC)

A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC)

Sponsor: Amgen

Conditions Breast Cancer

Interventions cyclophosphamide docetaxel doxorubicin hydrochloride neoadjuvant therapy zoledronic acid

Updated 6 times since 2017 Last updated: Jan 16, 2020 Started: Apr 30, 2010 Primary completion: Apr 30, 2012 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01099436, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Amgen, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Feb 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Borstkanker Onderzoek Groep
Dutch Cancer Society
Novartis
Sanofi

Data source: Borstkanker Onderzoek Groep

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leiden, Netherlands